BACKGROUND: Pyrazinamide (PZA) is a key drug in the treatment of tuberculosis (TB), including multidrug-resistant TB. Drug susceptibility testing (DST) of Mycobacterium tuberculosis against PZA is not included in the World Health Organization's yearly proficiency testing. There is an increasing need to establish quality control of PZA DST. OBJECTIVE: To evaluate the performance of PZA DST and to introduce a quality assurance system for the test in Sweden. METHOD: Panels with PZA-susceptible and -resistant isolates were used in three rounds of proficiency testing in all five Swedish clinical TB laboratories and our reference laboratory. All laboratories used the MGIT 960 system. Minimum inhibitory concentrations (MICs) were determined and the pncA gene was sequenced to further characterise the 52 panel strains. RESULTS: Good agreement was seen between the phenotypic PZA DST and pncA sequence data, and MIC determination confirmed high levels of resistance. However, in contrast to other drugs, for which correct proficiency test results were observed, specificity problems occurred for PZA DST in some laboratories. CONCLUSIONS: In Sweden, using panel testing, differences were seen in the proficiency of TB laboratories in correctly identifying PZA susceptibility. Improved results were noted in the third round; PZA has therefore been included in yearly proficiency testing.
BACKGROUND:Pyrazinamide (PZA) is a key drug in the treatment of tuberculosis (TB), including multidrug-resistant TB. Drug susceptibility testing (DST) of Mycobacterium tuberculosis against PZA is not included in the World Health Organization's yearly proficiency testing. There is an increasing need to establish quality control of PZA DST. OBJECTIVE: To evaluate the performance of PZA DST and to introduce a quality assurance system for the test in Sweden. METHOD: Panels with PZA-susceptible and -resistant isolates were used in three rounds of proficiency testing in all five Swedish clinical TB laboratories and our reference laboratory. All laboratories used the MGIT 960 system. Minimum inhibitory concentrations (MICs) were determined and the pncA gene was sequenced to further characterise the 52 panel strains. RESULTS: Good agreement was seen between the phenotypic PZA DST and pncA sequence data, and MIC determination confirmed high levels of resistance. However, in contrast to other drugs, for which correct proficiency test results were observed, specificity problems occurred for PZA DST in some laboratories. CONCLUSIONS: In Sweden, using panel testing, differences were seen in the proficiency of TB laboratories in correctly identifying PZA susceptibility. Improved results were noted in the third round; PZA has therefore been included in yearly proficiency testing.
Authors: Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony Journal: Antimicrob Agents Chemother Date: 2016-07-22 Impact factor: 5.191
Authors: Simone Mok; Emma Roycroft; Peter R Flanagan; Lorraine Montgomery; Emanuele Borroni; Thomas R Rogers; Margaret M Fitzgibbon Journal: Antimicrob Agents Chemother Date: 2021-07-16 Impact factor: 5.191
Authors: Paolo Miotto; Andrea M Cabibbe; Silke Feuerriegel; Nicola Casali; Francis Drobniewski; Yulia Rodionova; Daiva Bakonyte; Petras Stakenas; Edita Pimkina; Ewa Augustynowicz-Kopeć; Massimo Degano; Alessandro Ambrosi; Sven Hoffner; Mikael Mansjö; Jim Werngren; Sabine Rüsch-Gerdes; Stefan Niemann; Daniela M Cirillo Journal: mBio Date: 2014-10-21 Impact factor: 7.867
Authors: Glenn P Morlock; Frances C Tyrrell; Dorothy Baynham; Vincent E Escuyer; Nicole Green; Youngmi Kim; Patricia A Longley-Olson; Nicole Parrish; Courtney Pennington; Desmond Tan; Brett Austin; James E Posey Journal: Tuberc Res Treat Date: 2017-11-08
Authors: Martin Hunt; Phelim Bradley; Simon Grandjean Lapierre; Simon Heys; Mark Thomsit; Michael B Hall; Kerri M Malone; Penelope Wintringer; Timothy M Walker; Daniela M Cirillo; Iñaki Comas; Maha R Farhat; Phillip Fowler; Jennifer Gardy; Nazir Ismail; Thomas A Kohl; Vanessa Mathys; Matthias Merker; Stefan Niemann; Shaheed Vally Omar; Vitali Sintchenko; Grace Smith; Dick van Soolingen; Philip Supply; Sabira Tahseen; Mark Wilcox; Irena Arandjelovic; Tim E A Peto; Derrick W Crook; Zamin Iqbal Journal: Wellcome Open Res Date: 2019-12-02
Authors: Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie Journal: PLoS One Date: 2015-07-28 Impact factor: 3.240